• The full indication for SUNHARBO (asundexian) is to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] ≤15) or high-risk transient ischemic attack (TIA) in combination with antiplatelet therapy.1
• SUNHARBO is a first-in-class, once daily, Factor XIa inhibitor for secondary stroke prevention.1
• Approximately one in five people who had a stroke will have another stroke within five years, and secondary strokes often cause more devastating outcomes than first strokes.2

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.